Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Q4Q

Magacizumab Fab fragment in complex with human LRG1 epitope

Summary for 7Q4Q
Entry DOI10.2210/pdb7q4q/pdb
DescriptorMagacizumab light chain, Magacizumab heavy chain, LRG1 epitope, ... (5 entities in total)
Functional Keywordsantibody, cancer, angiogenesis, human, immune system
Biological sourceMus musculus
More
Total number of polymer chains6
Total formula weight98470.00
Authors
Gutierrez-Fernandez, J.,Luecke, H. (deposition date: 2021-11-01, release date: 2022-06-15, Last modification date: 2024-10-23)
Primary citationGutierrez-Fernandez, J.,Javaid, F.,De Rossi, G.,Chudasama, V.,Greenwood, J.,Moss, S.E.,Luecke, H.
Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential.
Acta Crystallogr D Struct Biol, 78:725-734, 2022
Cited by
PubMed Abstract: The formation of new dysfunctional blood vessels is a crucial stage in the development of various conditions such as macular degeneration, diabetes, cardiovascular disease, neurological disease and inflammatory disorders, as well as during tumor growth, eventually contributing to metastasis. An important factor involved in pathogenic angiogenesis is leucine-rich α-2-glycoprotein 1 (LRG1), the antibody blockade of which has been shown to lead to a reduction in both choroidal neovascularization and tumor growth in mouse models. In this work, the structural interactions between the LRG1 epitope and the Fab fragment of Magacizumab, a humanized function-blocking IgG4 against LRG1, are analysed, determining its specific binding mode and the key residues involved in LRG1 recognition. Based on these structural findings, a series of mutations are suggested that could be introduced into Magacizumab to increase its affinity for LRG1, as well as a model of the entire Fab-LRG1 complex that could enlighten new strategies to enhance affinity, consequently leading towards an even more efficient therapeutic.
PubMed: 35647920
DOI: 10.1107/S2059798322004132
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.65 Å)
Structure validation

235458

PDB entries from 2025-04-30

PDB statisticsPDBj update infoContact PDBjnumon